| abstract |
(A) 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin- Amine, (S) -pyrrolidine-1,2-dicarboxylic acid 2-amide 1 - ({4-Methyl- 5- [2- (2,2,2-trifluoro- -Aminol), or any pharmaceutically acceptable salt thereof, and (b) a gonadorelin agonist, or a pharmaceutically acceptable salt, solvate, solvate, And optionally, (c) a pharmaceutical combination comprising an anti-estrogen agent; The use of such a combination in the manufacture of a medicament for the treatment or prevention of cancer; A pharmaceutical composition of a combination of the above therapeutic agents; And administering to the subject a therapeutically effective amount of such a combination. |